Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-06T10:11:14.420Z Has data issue: false hasContentIssue false

Chapter 26 - Maternal and Fetal Therapy: Can We Optimize Fetal Growth?

from Fetal Growth and Well-being

Published online by Cambridge University Press:  21 October 2019

By
Katarzyna M. Maksym  and
Anna L. David
Edited by
Mark D. Kilby ,
Anthony Johnson  and
Dick Oepkes
Mark D. Kilby
Affiliation:
University of Birmingham
Anthony Johnson
Affiliation:
University of Texas Medical School at Houston
Dick Oepkes
Affiliation:
Leids Universitair Medisch Centrum
Get access

Summary

Difficulties with the diagnosis, management and treatment of fetal growth problems start with defining which small fetus or newborn is affected by fetal growth restriction (FGR). A small for gestational age (SGA) fetus is diagnosed when its estimated fetal weight (EFW), or its components such as abdominal circumference (AC), fall below the 10th centile for the given gestation. This definition will include both healthy small fetuses and those who fail to reach their growth potential and who are considered to have FGR. There are many factors known to contribute to the reduction of fetal growth velocity, such as chromosomal anomalies, genetic syndromes and infections as well as maternal and environmental factors, including poor periconceptual diet and cigarette smoking. Other known risk factors for FGR include maternal co-morbidities, especially preexisting hypertensive disorders, the use of assisted reproductive techniques, and obstetric complications like heavy, recurrent vaginal bleeding or loss of co-twin.

Type
Chapter
Information
Fetal Therapy
Scientific Basis and Critical Appraisal of Clinical Benefits
 , pp. 287 - 301
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Brosens, I, Pijnenborg, R, Benagiano, G. Defective myometrial spiral artery remodelling as a cause of major obstetrical syndromes in endometriosis and adenomyosis. Placenta. 2013; 34: 100–5.CrossRefGoogle ScholarPubMed
Lyall, F, Robson, SC, Bulmer, JN. Spiral artery remodeling and trophoblast invasion in preeclampsia and fetal growth restriction relationship to clinical outcome. Hypertension. 2013; 62: 1046–54.Google Scholar
Konje, JC, Howarth, ES, Kaufmann, P, Taylor, DJ. Longitudinal quantification of uterine artery blood volume flow changes during gestation in pregnancies complicated by intrauterine growth restriction. BJOG. 2003; 110: 301–5.Google Scholar
Savvidou, MD, Yu, CK, Harland, LC, Hingorani, AD, Nicolaides, KH. Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction. Am J Obstet Gynecol. 2006; 195: 1668–73.CrossRefGoogle ScholarPubMed
Timmermans, S, Steegers-Theunissen, RP, Vujkovic, M, den Breeijen, H, Russcher, H, Lindemans, J, et al. The Mediterranean diet and fetal size parameters: the Generation R Study. Br J Nutr. 2012; 108: 1399–409.CrossRefGoogle ScholarPubMed
Mahon, P, Harvey, N, Crozier, S, Inskip, H, Robinson, S, Arden, NK, et al. Low maternal vitamin D status and fetal bone development: cohort study. J Bone Min Res. 2010; 25: 14–19.Google Scholar
Stephenson, J, Heslehurst, N, Hall, J, Schoenaker, DAJM, Hutchinson, J, Cade, JE, et al. Before the beginning: nutrition and lifestyle in the preconception period and its importance for future health. Lancet. 2018; 391: 1830–41.Google Scholar
Fleming, TP, Watkins, AJ, Velazquez, MA, Mathers, JC, Prentice, AM, Stephenson, J, et al. Origins of lifetime health around the time of conception: causes and consequences. Lancet. 2018; 391: 1842–52.Google Scholar
Hillman, S, Peebles, DM, Williams, DJ. Paternal metabolic and cardiovascular risk factors for fetal growth restriction: a case–control study. Diabetes Care. 2013; 36: 1675–80.Google Scholar
Barker, M, Dombrowski, SU, Colbourn, T, Fall, CHD, Kriznik, NM, Lawrence, WT, et al. Intervention strategies to improve nutrition and health behaviours before conception. Lancet. 2018; 391: 1853–64.CrossRefGoogle ScholarPubMed
Knudsen, VK, Orozova-Bekkevold, IM, Mikkelsen, TB, Wolff, S, Olsen, SF. Major dietary patterns in pregnancy and fetal growth. Eur J Clin Nutr. 2008; 62: 463–70.CrossRefGoogle ScholarPubMed
Ota, E, Hori, H, Mori, R, Tobe-Gai, R, Farrar, D. Antenatal dietary education and supplementation to increase energy and protein intake. Cochrane Database Syst Rev. 2015; 6: CD000032.Google Scholar
Haider, BA, Bhutta, ZA. Multiple-micronutrient supplementation for women during pregnancy. Cochrane Database Syst Rev. 2017; 4: CD004905.Google Scholar
Peña-Rosas, JP, De-Regil, LM, Gomez Malave, H, Flores-Urrutia, MC, Dowswell, T. Intermittent oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 2015; 11: CD009997.Google Scholar
Peña-Rosas, JP, De-Regil, LM, Garcia-Casal, MN, Dowswell, T. Daily oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 2015; 7: CD004736.Google Scholar
World Health Organization. (2013). Guideline: Calcium supplementation in pregnant women. https://apps.who.int/iris/bitstream/handle/10665/85120/9789241505376_eng.pdf;jsessionid=3C099F930FA697D0A123C32272A8838D?sequence=1.Google Scholar
Hofmeyr, GJ, Lawrie, TA, Atallah, ÁN, Duley, L, Torloni, MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2014; 6: CD001059.Google Scholar
Rumbold, A, Duley, L, Crowther, CA, Haslam, RR. Antioxidants for preventing pre-eclampsia. Cochrane Database Syst Rev. 2008; 1: CD004227.Google Scholar
Han, Z, Mulla, S, Beyene, J, Liao, G, McDonald, SD, Knowledge Synthesis Group. Maternal underweight and the risk of preterm birth and low birth weight: a systematic review and meta-analyses. Int J Epidemiol. 2011; 40: 65–101.CrossRefGoogle ScholarPubMed
Yaktine, AL, Rasmussen, KM (eds.). Weight Gain During Pregnancy: Reexamining the Guidelines. Washington, DC: National Academies Press, 2009.Google Scholar
Radulescu, L, Munteanu, O, Popa, F, Cirstoiu, M. The implications and consequences of maternal obesity on fetal intrauterine growth restriction. J Med Life. 2013; 6: 292–8.Google Scholar
CARE Study Group. Maternal caffeine intake during pregnancy and risk of fetal growth restriction: a large prospective observational study. BMJ. 2008; 337: a2332.CrossRefGoogle Scholar
Wills, R-A, Coory, MD. Effect of smoking among Indigenous and non-Indigenous mothers on preterm birth and full-term low birthweight. Med J Aust. 2008; 189: 490–4.Google Scholar
Riisinen, S, Sankilampi, U, Gissler, M, Kramer, MR, Hakulinen-Viitanen, T, Saari, J, et al. Smoking cessation in the first trimester reduces most obstetric risks, but not the risks of major congenital anomalies and admission to neonatal care: a population-based cohort study of 1,164,953 singleton pregnancies in Finland. J Epidemiol Community Health. 2014; 68: 159–64.Google Scholar
Suzuki, K, Sato, M, Zheng, W, Shinohara, R, Yokomichi, H, Yamagata, Z. Effect of maternal smoking cessation before and during early pregnancy on fetal and childhood growth. J Epidemiol. 2014; 24: 60–6.Google Scholar
Lumley, J, Chamberlain, C, Dowswell, T, Oliver, S, Oakley, L, Watson, L. Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2009; 3: CD001055.Google Scholar
Abraham, M, Alramadhan, S, Iniguez, C, Duijts, L, Jaddoe, VW, Den Dekker, HT, et al. A systematic review of maternal smoking during pregnancy and fetal measurements with meta-analysis. PLoS ONE. 2017; 12: e0170946.CrossRefGoogle ScholarPubMed
Fergusson, DM, Horwood, LJ, Northstone, K. Maternal use of cannabis and pregnancy outcome. BJOG. 2002; 109: 21–7.Google Scholar
Gouin, K, Murphy, K, Shah, PS. Effects of cocaine use during pregnancy on low birthweight and preterm birth: Systematic review and metaanalyses. Am J Obstet Gynecol. 2011; 204: 340. e1–12.Google Scholar
Ladhani, NNN, Shah, PS, Murphy, KE. Prenatal amphetamine exposure and birth outcomes: a systematic review and metaanalysis. Am J Obstet Gynecol. 2011; 205: 219. e1–219. e7.Google Scholar
Whitehead, N, Lipscomb, L. Patterns of alcohol use before and during pregnancy and the risk of small-for-gestational-age birth. Am J Epidemiol. 2003; 158: 654–62.Google Scholar
Patra, J, Bakker, R, Irving, H, Jaddoe, V, Malini, S, Rehm, J. Dose-response relationship between alcohol consumption before and during pregnancy and the risks of low birthweight, preterm birth and small for gestational age (SGA) – a systematic review and meta-analyses. BJOG. 2011; 118: 1411–21.Google Scholar
Abalos, E, Duley, L, Steyn, DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2014; 1: CD002252.Google Scholar
Magee, LA, von Dadelszen, P, Rey, E, Ross, S, Asztalos, E, Murphy, KE, et al. Less-Tight versus Tight Control of Hypertension in Pregnancy. N Engl J Med. 2015; 372: 407–17.Google Scholar
Groom, KM, David, AL. The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction. Am J Obstet Gynecol. 2018; 218: S829–40.Google Scholar
Taubert, D, Berkels, R, Grosser, N, Schröder, H, Gründemann, D, Schömig, E. Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action. Br J Pharmacol. 2004; 143: 159–65.Google Scholar
Grosser, N, Abate, A, Oberle, S, Vreman, HJ, Dennery, PA, Becker, JC, et al. Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. Biochem Biophys Res Commun. 2003; 308: 956–60.CrossRefGoogle ScholarPubMed
Roberge, S, Nicolaides, K, Demers, S, Hyett, J, Chaillet, N, Bujold, E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2017; 216: 110–120. e6.CrossRefGoogle ScholarPubMed
Meher, S, Duley, L, Hunter, K, Askie, L. Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol. 2017; 216: 121–128. e2.CrossRefGoogle ScholarPubMed
Ayala, DE, Ucieda, R, Hermida, RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int. 2013; 30: 260–79.CrossRefGoogle ScholarPubMed
Hermida, RC, Ayala, DE, Iglesias, M. Administration time-dependent influence of aspirin on blood pressure in pregnant women. Hypertension. 2003; 41: 651–6.Google Scholar
McCowan, LM, Figueras, F, Anderson, NH. Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy. Am J Obstet Gynecol. 2018: 218: S855–68.CrossRefGoogle ScholarPubMed
Rolnik, DL, Wright, D, Poon, LC, O’Gorman, N, Syngelaki, A, de Paco Matallana, C, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017; 377: 613–22.CrossRefGoogle ScholarPubMed
Omri, A, Delaloye, JF, Andersen, H, Bachmann, F. Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy. Thromb Haemost. 1989; 61: 55–6.Google Scholar
Mousavi, S, Moradi, M, Khorshidahmad, T, Motamedi, M. Anti-Inflammatory effects of heparin and its derivatives: a systematic review. Adv Pharmacol Sci. 2015; 2015: 507151.Google Scholar
Oberkersch, R, Attorresi, AI, Calabrese, GC. Low-molecular-weight heparin inhibition in classical complement activation pathway during pregnancy. Thromb Res. 2010; 125: e240–5.Google Scholar
Mousa, SA, Petersen, LJ. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost. 2009; 102: 258–67.Google Scholar
Bose, P, Black, S, Kadyrov, M, Bartz, C, Shlebak, A, Regan, L, et al. Adverse effects of lupus anticoagulant positive blood sera on placental viability can be prevented by heparin in vitro. Am J Obstet Gynecol. 2004; 191: 2125–31.CrossRefGoogle ScholarPubMed
Sobel, ML, Kingdom, J, Drewlo, S. Angiogenic response of placental villi to heparin. Obstet Gynecol. 2011; 117: 1375–83.Google Scholar
Di Simone, N, Di Nicuolo, F, Sanguinetti, M, Ferrazzani, S, D’Alessio, MC, Castellani, R, et al. Low-molecular weight heparin induces in vitro trophoblast invasiveness: role of matrix metalloproteinases and tissue inhibitors. Placenta. 2007; 28: 298–304.Google Scholar
Yinon, Y, Ben Meir, E, Margolis, L, Lipitz, S, Schiff, E, Mazaki-Tovi, S, et al. Low molecular weight heparin therapy during pregnancy is associated with elevated circulatory levels of placental growth factor. Placenta. 2015; 36: 121–4.CrossRefGoogle ScholarPubMed
McLaughlin, K, Baczyk, D, Potts, A, Hladunewich, M, Parker, JD, Kingdom, JCP. Low molecular weight heparin improves endothelial function in pregnant women at high risk of Preeclampsia. Hypertension. 2016; 1–9.Google Scholar
Torricelli, M, Reis, FM, Florio, P, Severi, FM, Bocchi, C, Picciolini, E, et al. Low-molecular-weight heparin improves the performance of uterine artery Doppler velocimetry to predict preeclampsia and small-for-gestational age infant in women with gestational hypertension. Ultrasound Med Biol. 2006; 32: 1431–5.CrossRefGoogle ScholarPubMed
Abheiden, CNH, Van Hoorn, ME, Hague, WM, Kostense, PJ, Van Pampus, MG, De Vries, JIP. Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial Doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG. 2016; 123: 797–805.Google Scholar
de Vries, JIP, Hague, WM, van Pampus, MG. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. J Thromb Haemost. 2012; 10: 1196.Google Scholar
Rey, E, Garneau, P, David, M, Gauthier, R, Leduc, L, Michon, N, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost. 2009; 7: 58–64.Google Scholar
Mastrolia, SA, Novack, L, Thachil, J, Rabinovich, A, Pikovsky, O, Klaitman, V, et al. LMWH in the prevention of preeclampsia and fetal growth restriction in women without thrombophilia: a systematic review and meta-analysis. Thromb Haemost. 2016; 116: 868–78.Google Scholar
Say, L, Gülmezoglu, AM, Hofmeyr, GJ. Maternal oxygen administration for suspected impaired fetal growth. Cochrane Database Syst Rev. 2003; 1: CD000137.Google Scholar
David, AL, Thornton, S, Sutcliffe, A, Williams, P. (2015). Developing New Pharmaceutical Treatments for Obstetric Conditions. Royal College of Obstetricians & Gynaecologists. www.rcog.org.uk/globalassets/documents/guidelines/scientific-impact-papers/sip-50.pdfGoogle Scholar
Learmont, JG, Poston, L. Nitric oxide is involved in flow-induced dilation of isolated human small fetoplacental arteries. Am J Obstet Gynecol. 1996; 174: 583–8.Google Scholar
Duvekot, JJ, Cheriex, EC, Pieters, FAA, Menheere, PPCA, Schouten, HJA, Peeters, LLH. Maternal volume homeostasis in early pregnancy in relation to fetal growth restriction. Obstet Gynecol. 1995; 85: 361–7.CrossRefGoogle ScholarPubMed
Duvekot, JJ, Cheriex, EC, Pieters, FA, Peeters, LL. Severely impaired fetal growth is preceded by maternal hemodynamic maladaptation in very early pregnancy. Acta Obstet Gynecol Scand. 1995; 74: 693–7.CrossRefGoogle ScholarPubMed
Krause, BJ, Carrasco-Wong, I, Caniuguir, A, Carvajal, J, Farías, M, Casanello, P. Endothelial eNOS/arginase imbalance contributes to vascular dysfunction in IUGR umbilical and placental vessels. Placenta. 2013; 34: 20–8.CrossRefGoogle ScholarPubMed
Kulandavelu, S, Whiteley, KJ, Bainbridge, SA, Qu, D, Adamson, SL. Endothelial NO synthase augments fetoplacental blood flow, placental vascularization, and fetal growth in mice. Hypertension. 2013; 61: 259–66.Google Scholar
Kähler, C, Schleußner, E, Möller, A, Seewald, HJ. Nitric oxide donors: effects on fetoplacental blood flow. Eur J Obstet Gynecol Reprod Biol. 2004; 115: 10–14.Google Scholar
Meher, S, Duley, L. Nitric oxide for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007; 2: CD006490.Google Scholar
Tiralongo, G, Pisani, I, Vasapollo, B, Khalil, A, Thilaganathan, B, Valensise, H. Nitric oxide (NO) donors and haemodynamic changes in fetal growth restriction. Ultrasound Obstet Gynecol. 2018; 4: 514–18.Google Scholar
Ormesher, L, Myers, JE, Chmiel, C, Wareing, M, Greenwood, SL, Tropea, T, et al. Effects of dietary nitrate supplementation, from beetroot juice, on blood pressure in hypertensive pregnant women: a randomised, double-blind, placebo-controlled feasibility trial. Nitric Oxide. 2018; 80: 37–44.Google Scholar
Schleussner, E, Lehmann, T, Kähler, C, Schneider, U, Schlembach, D, Groten, T. Impact of the nitric oxide-donor pentaerythrityltetranitrate on perinatal outcome in risk pregnancies: a prospective, randomized, double-blinded trial. J Perinat Med. 2014; 42: 507–14.CrossRefGoogle ScholarPubMed
Wareing, M, Myers, JE, O’Hara, M, Kenny, LC, Warren, AY, Taggart, MJ, et al. Effects of a phosphodiesterase-5 (PDE5) inhibitor on endothelium-dependent relaxation of myometrial small arteries. Am J Obstet Gynecol. 2004; 190: 1283–90.Google Scholar
Wareing, M, Myers, JE, O’Hara, M, Baker, PN. Sildenafil citrate (Viagra) enhances vasodilatation in fetal growth restriction. J Clin Endocrinol Metab. 2005; 90: 2550–5.Google Scholar
Russo, FM, Conings, S, Allegaert, K, van Mieghem, T, Toelen, J, van Calsteren, K, et al. Sildenafil crosses the placenta at therapeutic levels in a dually perfused human cotyledon model. Am J Obstet Gynecol. 2018; 219: 619. e1-619. e10.Google Scholar
Walton, RB, Reed, LC, Estrada, SM, Schmiedecke, SS, Villazana-Kretzer, DL, Napolitano, PG, et al. Evaluation of sildenafil and tadalafil for reversing constriction of fetal arteries in a human placenta perfusion model. Hypertension. 2018; 72: 167–76.Google Scholar
Samangaya, RA, Mires, G, Shennan, A, Skillern, L, Howe, D, McLeod, A, et al. A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. Hypertens Pregnancy. 2009; 28: 369–82.Google Scholar
Oyston, C, Stanley, JL, Oliver, MH, Bloomfield, FH, Baker, PN. Maternal administration of sildenafil citrate alters fetal and placental growth and fetal-placental vascular resistance in the growth-restricted ovine fetus. Hypertension. 2016; 68: 760–7.Google Scholar
Miller, SL, Loose, JM, Jenkin, G, Wallace, EM. The effects of sildenafil citrate (Viagra) on uterine blood flow and well being in the intrauterine growth-restricted fetus. Am J Obstet Gynecol. 2009; 200: 102. e1–7.Google Scholar
Von Dadelszen, P, Dwinnell, S, Magee, LA, Carleton, BC, Gruslin, A, Lee, B, et al. Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. BJOG. 2011; 118: 624–8.Google Scholar
Adel El-Sayed, M, Abdel-Aty Saleh, S, Ahmed Maher, M, Khidre, AM. Utero-placental perfusion Doppler indices in growth restricted fetuses: effect of sildenafil citrate. J Matern Fetal Neonatal Med. 2018; 31: 1045–50.Google Scholar
Ganzevoort, W, Alfirevic, Z, von Dadelszen, P, Kenny, L, Papageorghiou, A, van Wassenaer-Leemhuis, A, et al. STRIDER: Sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction? A protocol for a systematic review with individual participant data and aggregate data meta-analysis and trial sequential analysis. Syst Rev. 2014; 3: 23.CrossRefGoogle ScholarPubMed
Pels, A, Kenny, LC, Alfirevic, Z, Baker, PN, von Dadelszen, P, Gluud, C, et al. STRIDER (Sildenafil TheRapy in dismal prognosis early onset fetal growth restriction): an international consortium of randomised placebo-controlled trials. BMC Pregnancy Childbirth. 2017; 17: 440.Google Scholar
Sharp, A, Cornforth, C, Jackson, R, Harrold, J, Turner, MA, Kenny, LC, et al. Maternal sildenafil for severe fetal growth restriction (STRIDER ): a multicentre, randomised, placebo-controlled, double-blind trial. Lancet Child Adolesc Health. 2018; 2: 93–102.CrossRefGoogle ScholarPubMed
Groom, KM, Ganzevoort, W, Alfirevic, Z, Lim, K, Papageorghiou, AT. Clinicians should stop prescribing sildenafil for fetal growth restriction (FGR): comment from the STRIDER Consortium. Ultrasound Obstet Gynecol. 2018; 52: 295–6.Google Scholar
Tanaka, K, Tanaka, H, Maki, S, Kubo, M, Nii, M, Magawa, S, et al. Cardiac function and tadalafil used for treating fetal growth restriction in pregnant women without cardiovascular disease. J Matern Neonatal Med. 2018; 20: 1–3.Google Scholar
Kubo, M, Umekawa, T, Maekawa, Y, Tanaka, H, Nii, M, Murabayashi, N, et al. Retrospective study of tadalafil for fetal growth restriction: impact on maternal and perinatal outcomes. J Obstet Gynaecol Res. 2017; 43: 291–7.Google Scholar
Tanaka, H, Kubo, M, Nii, M, Maki, S, Umekawa, T, Ikeda, T. Treatment using tadalafil for severe pre-eclampsia with fetal growth restriction. J Obstet Gynaecol Res. 2017; 43: 1205–8.CrossRefGoogle ScholarPubMed
Sakamoto, M, Osato, K, Kubo, M, Nii, M, Tanaka, H, Murabayashi, N, et al. Early-onset fetal growth restriction treated with the long-acting phosphodiesterase-5 inhibitor tadalafil: a case report. J Med Case Rep. 2016; 10: 1–5.CrossRefGoogle ScholarPubMed
Kubo-Kaneda, M, Tanaka, H, Maki, S, Nii, M, Umekawa, T, Osato, K, et al. Placental growth factor as a predictor of the efficacy of tadalafil treatment for fetal growth restriction. J Matern Neonatal Med. 2018; 0: 1–4.Google Scholar
Belo, L, Caslake, M, Santos-Silva, A, Castro, EMB, Pereira-Leite, L, Quintanilha, A, et al. LDL size, total antioxidant status and oxidised LDL in normal human pregnancy: a longitudinal study. Atherosclerosis. 2004; 177: 391–9.Google Scholar
Bauer, AJ, Banek, CT, Needham, K, Gillham, H, Capoccia, S, Regal, JF, et al. Pravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension. Hypertension. 2013; 61: 1103–10.Google Scholar
Yang, M-Y, Diao, Z-Y, Wang, Z-Y, Yan, G-J, Zhao, G-F, Zheng, M-M, et al. Pravastatin alleviates lipopolysaccharide-induced placental TLR4 over-activation and promotes uterine arteriole remodeling without impairing fetal development of rats. J Biomed Res. 2018; 32: 288–97.Google Scholar
Ofori, B, Oraichi, D, Blais, L, Rey, E, Berard, A. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: a nested case-control study. Birth Defects Res B Dev Reprod Toxicol. 2006; 77: 268–79.CrossRefGoogle ScholarPubMed
Kane, AD, Herrera, EA, Hansell, JA, Giussani, DA. Statin treatment depresses the fetal defence to acute hypoxia via increasing nitric oxide bioavailability. J Physiol. 2012; 590: 323–34.Google Scholar
Costantine, MM, Cleary, K. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol. 2013; 121: 349–53.Google Scholar
Lefkou, E, Mamopoulos, A, Dagklis, T, Vosnakis, C, Rousso, D, Girardi, G. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest. 2016; 126: 2933–40.Google Scholar
Kaitu’u-Lino, TJ, Brownfoot, FC, Beard, S, Cannon, P, Hastie, R, Nguyen, TV, et al. Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction – implications for treating preeclampsia. PLoS ONE. 2018; 13: 1–14.Google Scholar
Cluver, CA, Walker, SP, Mol, BW, Theron, GB, Hall, DR, Hiscock, R, et al. Double blind, randomised, placebo-controlled trial to evaluate the efficacy of esomeprazole to treat early onset pre-eclampsia (PIE Trial): a study protocol. BMJ Open. 2015; 5: e008211.Google Scholar
Wang, M-J, Cai, W-J, Li, N, Ding, Y-J, Chen, Y, Zhu, Y-C. The hydrogen sulfide donor NaHS promotes angiogenesis in a rat model of hind limb ischemia. Antioxid Redox Signal. 2010; 12: 1065–77.CrossRefGoogle Scholar
Cindrova-Davies, T, Herrera, EA, Niu, Y, Kingdom, J, Giussani, DA, Burton, GJ. Reduced cystathionine γ-lyase and increased miR-21 expression are associated with increased vascular resistance in growth-restricted pregnancies: hydrogen sulfide as a placental vasodilator. Am J Pathol. 2013; 182: 1448–58.Google Scholar
Holwerda, KM, Burke, SD, Faas, MM, Zsengeller, Z, Stillman, IE, Kang, PM, et al. Hydrogen sulfide attenuates sFlt1-induced hypertension and renal damage by upregulating vascular endothelial growth factor. J Am Soc Nephrol. 2014; 25: 717–25.Google Scholar
Wang, Y, Walli, AK, Schulze, A, Blessing, F, Fraunberger, P, Thaler, C, et al. Heparin-mediated extracorporeal low density lipoprotein precipitation as a possible therapeutic approach in preeclampsia. Transfus Apher Sci. 2006; 35: 103–10.CrossRefGoogle ScholarPubMed
David, AL, Torondel, B, Zachary, I, Wigley, V, Nader, KA, Mehta, V, et al. Local delivery of VEGF adenovirus to the uterine artery increases vasorelaxation and uterine blood flow in the pregnant sheep. Gene Ther. 2008; 15: 1344–50.Google Scholar
Mehta, V, Abi-Nader, K, Peebles, D, Benjamin, E, Wigley, V, Torondel, B, et al. Long-term increase in uterine blood flow is achieved by local overexpression of VEGF-A(165) in the uterine arteries of pregnant sheep. Gene Ther. 2012; 19: 925–35.Google Scholar
Carr, DJ, Aitken, RP, Milne, JS, Peebles, DM, Martin, JF, Zachary, IC, et al. Prenatal Ad.VEGF gene therapy – a promising new treatment for fetal growth restriction. Hum Gene Ther. 2011; 22: A128.Google Scholar
Carr, DJ, Wallace, JM, Aitken, R, Milne, JS, Martin, JF, Zachary, IZ, et al. Peri- and postnatal effects of prenatal adenoviral VEGF gene therapy in growth-restricted sheep. Biol Reprod. 2016; 94: 142.Google Scholar
Swanson, AM, Rossi, CA, Ofir, K, Mehta, V, Boyd, M, Barker, H, et al. Maternal therapy with Ad.VEGF-A165 increases fetal weight at term in a guinea pig model of fetal growth restriction. Hum Gene Ther. 2016; 27: 997–1007.Google Scholar
Vaughan, OR, Rossi, CA, Ginsberg, Y, White, A, Hristova, M, Sebire, NJ, et al. Perinatal and long-term effects of maternal uterine artery adenoviral VEGF-A165 gene therapy in the growth-restricted guinea pig fetus. Am J Physiol Regul Integr Comp Physiol. 2018; 315: R344–53.CrossRefGoogle ScholarPubMed
David, AL. Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth restriction. Placenta. 2017; 59 (Suppl. 1): S44–50.Google Scholar
Sheppard, M, Spencer, RN, Ashcroft, R, David, AL. Ethics and social acceptability of a proposed clinical trial using maternal gene therapy to treat severe early-onset fetal growth restriction. Ultrasound Obstet Gynecol. 2016; 47: 484–91.Google Scholar
Spencer, R, Ambler, G, Brodszki, J, Diemert, A, Figueras, F, Gratacós, E, et al. EVERREST prospective study: a 6-year prospective study to define the clinical and biological characteristics of pregnancies affected by severe early onset fetal growth restriction. BMC Pregnancy Childbirth. 2017; 17: 43.Google Scholar
Royal College of Obstetricians and Gynaecologists. (2007). The Role of Emergency and Elective Interventional Radiology in Postpartum Haemorrhage. www.rcog.org.uk/globalassets/documents/guidelines/goodpractice6roleemergency2007.pdf.Google Scholar
Camacho-Hübner, C, Woods, KA, Clark, AJL, Savage, MO. Insulin-like growth factor (IGF)-I gene deletion. Rev Endocr Metab Disord. 2002; 3: 357–61.Google Scholar
Jones, HN, Crombleholme, T, Habli, M. Adenoviral-mediated placental gene transfer of IGF-1 corrects placental insufficiency via enhanced placental glucose transport mechanisms. PLoS ONE. 2013; 8: e74632.Google Scholar
Harris, LK. Could peptide-decorated nanoparticles provide an improved approach for treating pregnancy complications? Nanomedicine. 2016; 11: 2235–8.Google Scholar
King, A, Ndifon, C, Lui, S, Widdows, K, Kotamraju, VR, Agemy, L, et al. Tumor-homing peptides as tools for targeted delivery of payloads to the placenta. Sci Adv. 2016; 2: e1600349.CrossRefGoogle ScholarPubMed
Cureton, N, Korotkova, I, Baker, B, Greenwood, S, Wareing, M, Kotamraju, R, et al. Selective targeting of a novel vasodilator to the uterine vasculature to treat impaired uteroplacental perfusion in pregnancy. Theranostics. 2017; 7: 3715–31.Google Scholar
Phillips, TJ, Scott, H, Menassa, DA, Bignell, AL, Sood, A, Morton, JS, et al. Treating the placenta to prevent adverse effects of gestational hypoxia on fetal brain development. Sci Rep. 2017; 7: 9079.Google Scholar
Beards, F, Jones, LE, Charnock, J, Forbes, K, Harris, LK. Placental homing peptide-microRNA inhibitor conjugates for targeted enhancement of intrinsic placental growth signaling. Theranostics. 2017; 7: 2940–55.CrossRefGoogle ScholarPubMed
Vasapollo, B, Lo Presti, D, Gagliardi, G, Farsetti, D, Tiralongo, GM, Pisani, I, et al. Restricted physical activity in pregnancy reduces maternal vascular resistance and improves fetal growth. Ultrasound Obstet Gynecol. 2018; 51: 672–6.CrossRefGoogle ScholarPubMed
Renshall, LJ, Morgan, HL, Moens, H, Cansfield, D, Finn-Sell, SL, Tropea, T, et al. Melatonin increases fetal weight in wild-type mice but not in mouse models of fetal growth restriction. Front Physiol. 2018; 9: 1–11.Google Scholar
Castillo-Melendez, M, Yawno, T, Sutherland, A, Jenkin, G, Wallace, EM, Miller, SL. Effects of antenatal melatonin treatment on the cerebral vasculature in an ovine model of fetal growth restriction. Dev Neurosci. 2017; 39: 323–37.Google Scholar
Chang, EY, Barbosa, E, Paintlia, MK, Singh, A, Singh, I. The use of N-acetylcysteine for the prevention of hypertension in the reduced uterine perfusion pressure model for preeclampsia in Sprague-Dawley rats. Am J Obstet Gynecol. 2005; 193: 952–6.Google Scholar
Hashimoto, K, Pinkas, G, Evans, L, Liu, H, Al-Hasan, Y, Thompson, LP. Protective effect of N-acetylcysteine on liver damage during chronic intrauterine hypoxia in fetal guinea pig. Reprod Sci. 2012; 19: 1001–9.Google Scholar
Roes, EM, Raijmakers, MT, Boo, TM, de Zusterzeel, PL, Merkus, HM, Peters, WH, et al. Oral N-acetylcysteine administration does not stabilise the process of established severe preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2006; 127: 61–7.Google Scholar
LaRosa, DA, Ellery, SJ, Parkington, HC, Snow, RJ, Walker, DW, Dickinson, H. Maternal creatine supplementation during pregnancy prevents long-term changes in diaphragm muscle structure and function after birth asphyxia. Pediatr Res. 2016; 80: 852–60.Google Scholar
Dickinson, H, Davies-Tuck, M, Ellery, S, Grieger, J, Wallace, E, Snow, R, et al. Maternal creatine in pregnancy: a retrospective cohort study. BJOG. 2016; 123: 1830–8.Google Scholar
Dickinson, H, Bain, E, Wilkinson, D, Middleton, P, Crowther, CA, Walker, DW. Creatine for women in pregnancy for neuroprotection of the fetus. Cochrane Database Syst Rev. 2014; 12: CD010846.Google Scholar
Rodger, MA, Gris, JC, de Vries, JIP, et al. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet. 2016; 388: 2629–41.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×